List view / Grid view
Lipid nanoparticles have been used to encapsulate CRISPR-Cas9 and deliver it to cells in mice, where it was highly effective at knocking down expression of a target protein.
The scientists discovered that dual knockout of genes in organoids grown from human tissue can generate a model of a potential therapeutic target for gastroesophageal junction cancer.
This exclusive interview highlights some of Dr Arthur Suckow’s insights into how his team uses RNA therapies to treat rare diseases such as Charcot-Marie-Tooth 1A.
Dr Sheraz Gul examines how patient-driven imaging strategies can be utilised to aid the translation of initial research all the way into the clinic.
Japanese researchers showed for the first time processes that are crucial targets for treating liver cancer are enhanced by saturated fatty acid diets.
The research has shown in high-resolution detail how certain lipids interact with pacemaker ion channels to enhance their activity.
The molecules, called SGDGs, may lead to new ways to treat age-related neurological diseases.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
A new single-cell nanoparticle targeting-sequencing approach can measure the cellular uptake of lipid nanoparticles carrying mRNA therapies.
A new genetic discovery adds weight to a theory that motor neurone diseases are caused by abnormal lipid processing pathways inside brain cells.
In their latest study, researchers at Moffitt Cancer Center have shown that cancer cells in an acidic environment undergo lipid synthesis and accumulation.
The University at Buffalo has received a $2.3 million grant from the US National Cancer Institute to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.
Researchers have been able to reduce the chronic inflammation associated with multiple sclerosis in a mice model of the disease, by administering one of the resolving lipid mediators of inflammation, Maresin-1.
Dr John Lewis, CEO of Entos Pharmaceuticals, outlines how an innovative proteolipid platform could enable a new class of DNA-based vaccines in this article.
New Bristol Myers Squibb research has revealed details about the structure of the protein receptor CD47, which helps protect cells from the human immune system.
